Celldex is evolving from a single-indication company focused on chronic urticaria to a broader platform immunology firm by leveraging barzolvolimab’s mast-cell depletion mechanism. The company has a strong cash position of $518.6 million projected at the end of 2025, bolstered by $345 million raised in April 2026, supporting operations through 2027 and reducing dilution risk. Phase 3 enrollment for chronic spontaneous urticaria (CSU) finished six months early, with top-line data expected in Q4 2026 and a Biologics License Application (BLA) filing planned for 2027. Success in additional indications such as ColdU, SD, PN, and AD could transform Celldex’s valuation from a single-asset to a multi-indication platform, opening multiple commercial opportunities.
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
Bitcoin (BTC) is showing signs of recovery after a prolonged downtrend, breaking above its 26-day and 50-day exponential moving averages (EMAs) near $63,400 and $64,100 respectively. This technical rebound suggests strengthening short-term momentum a...
ETHSystems, a new Ethereum-focused non-profit backed by Bitmine Immersion Technologies and Ethereum co-founder Joe Lubin, aims to enhance privacy on the Ethereum network for institutional use. This marks the third non-profit stepping in as the Ethere...
Lockheed Martin Ventures, the $1 billion venture capital arm of Lockheed Martin, is expanding into the UK and Europe with a new London office. It plans to invest at least $100 million in defense technology startups to strengthen transatlantic defense...
